Orexo AB has agreed to advance the successful exploratory feasibility study initiated with Swedish Orphan Biovitrum AB (Sobi) last year, which primarily assessed whether one of its biomolecules could be formulated in the AmorphOX drug delivery platform with retained activity.
 
The continued collaboration will evaluate if the AmorphOX technology could add unique properties to one of Sobi’s biomolecules.
 
Orexo has tested enzymes, peptides and proteins in AmorphOX and seen retained activity and significant improvement in stability compared to other formulations in a wide range of storage temperatures. A core strategy to expand the use of AmorphOX is to test AmorphOX in combination with molecules controlled by other companies. Sobi is the second company agreeing to advance the project beyond the initial exploratory feasibility study.  
 
Nikolaj Sørensen, President and CEO of Orexo, said, “Sobi is a leading biopharmaceutical company, and we are pleased to see how the unique properties of AmorphOX can be successfully applied to one of Sobi’s biomolecules. Advancing the collaboration is another proof of concept for AmorphOX and with the combined expertise of the companies I am certain we can learn more about the value potential for our scalable drug delivery platform. The collaboration is still in an early development stage, but with the ambition to continue show successful results, the collaboration has the potential to proceed into a development program of a new and differentiated pharmaceutical product.”